- Home
- ICAD vs MRSN Comparison
ICAD vs MRSN Comparison
Compare ICAD & MRSN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ICAD
- MRSN
- Stock Information
- Founded
- ICAD 1984
- MRSN 2001
- Country
- ICAD United States
- MRSN United States
- Employees
- ICAD N/A
- MRSN N/A
- Industry
- ICAD Medical/Dental Instruments
- MRSN Biotechnology: Pharmaceutical Preparations
- Sector
- ICAD Health Care
- MRSN Health Care
- Exchange
- ICAD Nasdaq
- MRSN Nasdaq
- Market Cap
- ICAD 87.5M
- MRSN 71.9M
- IPO Year
- ICAD 1986
- MRSN 2017
- Fundamental
- Price
- ICAD $2.03
- MRSN $0.34
- Analyst Decision
- ICAD
- MRSN Buy
- Analyst Count
- ICAD 0
- MRSN 3
- Target Price
- ICAD N/A
- MRSN $4.00
- AVG Volume (30 Days)
- ICAD 270.6K
- MRSN 3.1M
- Earning Date
- ICAD 03-19-2025
- MRSN 03-03-2025
- Dividend Yield
- ICAD N/A
- MRSN N/A
- EPS Growth
- ICAD N/A
- MRSN N/A
- EPS
- ICAD N/A
- MRSN N/A
- Revenue
- ICAD $19,608,000.00
- MRSN $40,497,000.00
- Revenue This Year
- ICAD $2.39
- MRSN N/A
- Revenue Next Year
- ICAD $13.71
- MRSN N/A
- P/E Ratio
- ICAD N/A
- MRSN N/A
- Revenue Growth
- ICAD 13.22
- MRSN 9.88
- 52 Week Low
- ICAD $1.18
- MRSN $0.34
- 52 Week High
- ICAD $3.78
- MRSN $4.64
- Technical
- Relative Strength Index (RSI)
- ICAD 38.33
- MRSN 29.11
- Support Level
- ICAD $2.05
- MRSN $0.41
- Resistance Level
- ICAD $2.48
- MRSN $0.42
- Average True Range (ATR)
- ICAD 0.16
- MRSN 0.04
- MACD
- ICAD -0.00
- MRSN -0.00
- Stochastic Oscillator
- ICAD 8.33
- MRSN 3.43
About ICAD iCAD Inc.
icad Inc is a medical technology company providing cancer detection and therapy solutions. The Company operates in one segment: Detection. The Detection segment include advanced image analysis and workflow solutions that enable healthcare professionals to serve patients by identifying pathologies, comprehensive range of high-performance, Artificial Intelligence and Computer-Aided Detection (CAD) systems and workflow solutions for 2D and 3D mammography, Magnetic Resonance Imaging and Computed Tomography. The company geographically operates in France, Belgium, Italy, Germany, Switzerland and All other.
About MRSN Mersana Therapeutics Inc.
Mersana Therapeutics Inc is a clinical-stage biopharmaceutical company using its differentiated and proprietary ADC platforms to develop targeted drugs with increased tolerability and expanded opportunities to deliver meaningful clinical benefits to patients. The Company's early stage programs includes XMT-1660, a Dolasynthen ADC targeting B7-H4, as well as XMT-2056, a STING agonist ADC developed using the Company's Immunosynthen platform and targeting a novel epitope of human epidermal growth factor receptor 2. The Company also has two earlier stage preclinical candidates, XMT-2068 and XMT-2175, both of which leverage the Company's Immunosynthen platform and target tumor-associated antigens.